Statistiche di base
| CIK | 1491576 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to TESARO, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| February 13, 2019 |
TSRO / TESARO, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TESARO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 881569107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 12, 2019 |
TSRO / TESARO, Inc. / VANGUARD GROUP INC Passive Investment tesaroinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: TESARO Inc Title of Class of Securities: Common Stock CUSIP Number: 881569107 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to designate th |
|
| February 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-35587 TESARO, INC. (Exact name of registrant as specified in its charte |
|
| February 1, 2019 |
TSRO / TESARO, Inc. / VANGUARD SPECIALIZED FUNDS Passive Investment tesaro.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.:1 )* Name of issuer: TESARO Inc Title of Class of Securities: Common Stock CUSIP Number: 881569107 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to designate the ru |
|
| January 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* TESARO, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 881569107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Address and T |
|
| January 24, 2019 |
EX-4.1 2 a19-10625ex4d1.htm EX-4.1 Exhibit 4.1 SECOND SUPPLEMENTAL INDENTURE THIS SECOND SUPPLEMENTAL INDENTURE (this “Second Supplemental Indenture”) dated as of January 22, 2019 between TESARO, INC. (the “Company”) and U.S. BANK NATIONAL ASSOCIATION, as trustee under the Indenture referred to below (the “Trustee”). All capitalized terms used but not otherwise defined herein shall have the respec |
|
| January 24, 2019 |
EX-99.1 3 a19-10625ex99d1.htm EX-99.1 Exhibit 99.1 TESARO, Inc. Provides Notice of Fundamental Change, Conversion Rate Adjustment pursuant to Make-Whole Adjustment Event and Supplemental Indenture WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) — TESARO, Inc. (the “Company” or “TESARO”), an oncology-focused biopharmaceutical company, today announced that pursuant to the terms of the Indenture and t |
|
| January 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2019 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of (Commission (I.R.S. Employer incorpo |
|
| January 22, 2019 |
As filed with the Securities and Exchange Commission on January 22, 2019 Registration No. |
|
| January 22, 2019 |
As filed with the Securities and Exchange Commission on January 22, 2019 Registration No. |
|
| January 22, 2019 |
As filed with the Securities and Exchange Commission on January 22, 2019 Registration No. |
|
| January 22, 2019 |
As filed with the Securities and Exchange Commission on January 22, 2019 Registration No. |
|
| January 22, 2019 |
As filed with the Securities and Exchange Commission on January 22, 2019 Registration No. |
|
| January 22, 2019 |
As filed with the Securities and Exchange Commission on January 22, 2019 Registration No. |
|
| January 22, 2019 |
As filed with the Securities and Exchange Commission on January 22, 2019 Registration No. |
|
| January 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2019 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of (Commission (I.R.S. Employer incorpo |
|
| January 22, 2019 |
Amended and Restated Bylaws of TESARO, Inc. EX-3.2 3 a19-10626ex3d2.htm EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS OF TESARO, INC. ARTICLE I OFFICES SECTION 1.1 REGISTERED OFFICE. The registered office shall be established and maintained at the office of Corporation Service Company, in the City of Wilmington, in the county of New Castle, in the State of Delaware, and said corporation shall be the registered agent of this corpora |
|
| January 22, 2019 |
Amended and Restated Certificate of Incorporation of TESARO, Inc. Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TESARO, INC. ARTICLE I Name The name of the corporation is TESARO, Inc. (the “Corporation”). ARTICLE II Registered Office and Registered Agent The address of the registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of the registered agen |
|
| January 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 7) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TESARO, Inc. (Name of Subject Company) TESARO, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (C |
|
| January 22, 2019 |
Issued: 22 January 2019, London UK – LSE Announcement EX-99.(A)(5(K) 2 d693898dex99a5k.htm EX-(A)(5(K) Exhibit (a)(5)(k) PRESS RELEASE Issued: 22 January 2019, London UK – LSE Announcement GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, fo |
|
| January 22, 2019 |
GSK / GlaxoSmithKline plc SC TO-T/A SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 7) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TESARO, INC. (Name of Subject Company (Issuer)) ADRIATIC ACQUISITION CORPORATION, GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE PLC (Names of Filing Persons (Offerors)) Common Stock, par value $0.0001 per shar |
|
| January 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 6) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TESARO, Inc. (Name of Subject Company) TESARO, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (C |
|
| January 17, 2019 |
Equity Considerations in Connection with GlaxoSmithKline Transaction Exhibit (a)(5)(F) Equity Considerations in Connection with GlaxoSmithKline Transaction Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. |
|
| January 17, 2019 |
EX-(d)(9) Exhibit (d)(9) January 16, 2019 Dr. Mary Lynne Hedley Retention Letter Agreement Dear Mary Lynne: As you know, GlaxoSmithKline plc (“GSK”) has entered into that certain Agreement and Plan of Merger, dated as of December 3, 2018 (the “Merger Agreement”), among GSK, Adriatic Acquisition Corporation, an indirect wholly-owned subsidiary of GSK (“Purchaser”) and Tesaro, Inc. (“Tesaro”). Pursu |
|
| January 17, 2019 |
GSK / GlaxoSmithKline plc SC TO-T/A SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 6) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TESARO, INC. (Name of Subject Company (Issuer)) ADRIATIC ACQUISITION CORPORATION, GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE PLC (Names of Filing Persons (Offerors)) Common Stock, par value $0.0001 per shar |
|
| January 17, 2019 |
EX-(d)(10) Exhibit (d)(10) January 16, 2019 Mr. Martin Huber Retention Letter Dear Martin, As you know, GlaxoSmithKline plc (“GSK”) has entered into that certain Agreement and Plan of Merger, dated as of December 3, 2018 (the “Merger Agreement”), among GSK, Adriatic Acquisition Corporation, an indirect wholly-owned subsidiary of GSK (“Purchaser”) and Tesaro, Inc. (“Tesaro”). Pursuant to the terms |
|
| January 17, 2019 |
EX-99.(D)(8) 2 d690355dex99d8.htm EX-(D)(8) Exhibit (d)(8) January 16, 2019 Mr. Grant Bogle Retention Letter Agreement Dear Grant, As you know, GlaxoSmithKline plc (“GSK”) has entered into that certain Agreement and Plan of Merger, dated as of December 3, 2018 (the “Merger Agreement”), among GSK, Adriatic Acquisition Corporation, an indirect wholly-owned subsidiary of GSK (“Purchaser”) and Tesaro, |
|
| January 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TESARO, Inc. (Name of Subject Company) TESARO, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (C |
|
| January 15, 2019 |
GlaxoSmithKline Extends Tender Offer for TESARO, Inc. EX-99.(A)(5)(J) Exhibit (a)(5)(j) GlaxoSmithKline Extends Tender Offer for TESARO, Inc. London, UK — January 15, 2019 — GlaxoSmithKline plc (LSE/NYSE: GSK) (“GSK”) today announces that its indirect wholly-owned subsidiary Adriatic Acquisition Corporation (“AAC”) has extended the expiration date of the previously announced cash tender offer to purchase all of the issued and outstanding shares (each |
|
| January 15, 2019 |
GSK / GlaxoSmithKline plc SC TO-T/A SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 5) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TESARO, INC. (Name of Subject Company (Issuer)) ADRIATIC ACQUISITION CORPORATION, GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE PLC (Names of Filing Persons (Offerors)) Common Stock, par value $0.0001 per shar |
|
| January 10, 2019 |
TSRO / TESARO, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10 )* TESARO, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 881569107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TESARO, Inc. (Name of Subject Company) TESARO, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (C |
|
| January 7, 2019 |
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE Exhibit a(5)(D) IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE RICHARD SCARANTINO, Individually and ) On Behalf of All Others Similarly Situated, ) ) Plaintiff, ) Case No. |
|
| January 7, 2019 |
GSK / GlaxoSmithKline plc SC TO-T/A SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TESARO, INC. (Name of Subject Company (Issuer)) ADRIATIC ACQUISITION CORPORATION, GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE PLC (Names of Filing Persons (Offerors)) Common Stock, par value $0.0001 per shar |
|
| January 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TESARO, Inc. (Name of Subject Company) TESARO, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (C |
|
| January 2, 2019 |
GSK / GlaxoSmithKline plc SC TO-T/A SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 3) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TESARO, INC. (Name of Subject Company (Issuer)) ADRIATIC ACQUISITION CORPORATION, GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE PLC (Names of Filing Persons (Offerors)) Common Stock, par value $0.0001 per shar |
|
| December 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TESARO, Inc. (Name of Subject Company) TESARO, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (C |
|
| December 18, 2018 |
GSK / GlaxoSmithKline plc SC TO-T/A SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TESARO, INC. (Name of Subject Company (Issuer)) ADRIATIC ACQUISITION CORPORATION, GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE PLC (Names of Filing Persons (Offerors)) Common Stock, par value $0.0001 per shar |
|
| December 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TESARO, Inc. (Name of Subject Company) TESARO, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (C |
|
| December 17, 2018 |
GSK / GlaxoSmithKline plc SC TO-T/A SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TESARO, INC. (Name of Subject Company (Issuer)) ADRIATIC ACQUISITION CORPORATION, GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE PLC (Names of Filing Persons (Offerors)) Common Stock, par value $0.0001 per shar |
|
| December 14, 2018 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 14, 2018 |
EX-(d)(6) Exhibit (d)(6) November 23, 2018 PRIVATE AND CONFIDENTIAL GlaxoSmithKline plc 980 Great West Road Brentford Middlesex TW8 96S Attention: Kevin Sin, Senior Vice President Dear Kevin: This letter agreement (the “Letter Agreement”) sets forth certain understandings between GlaxoSmithKline plc (“GSK”) and Tesaro, Inc. |
|
| December 14, 2018 |
EX-(d)(7) Exhibit (d)(7) DATED 3 December 2018 GLAXOSMITHKLINE PLC as the Original Borrower and the Guarantor BANK OF AMERICA MERRILL LYNCH INTERNATIONAL DESIGNATED ACTIVITY COMPANY as the Arranger THE FINANCIAL INSTITUTION listed in Schedule 1 as the Original Lender BANK OF AMERICA MERRILL LYNCH INTERNATIONAL DESIGNATED ACTIVITY COMPANY as the Agent $5,000,000,000 AND £3,500,000,000 FACILITIES AGREEMENT Slaughter and May One Bunhill Row London EC1Y 8YY (GO/OIS/CWM/RGM) CONTENTS Clause Page 1. |
|
| December 14, 2018 |
EX-99.(A)(1)(E) 6 d651999dex99a1e.htm EX-(A)(1)(E) Exhibit (a)(1)(e) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as described below). The Offer (as described below) is made only by the Offer to Purchase (as described below, dated as of December 14, 2018 and the related Letter of Transmittal (as described below) and any amendments or supplements |
|
| December 14, 2018 |
MUTUAL NON-DISCLOSURE AGREEMENT EX-(d)(3) Exhibit (d)(3) MUTUAL NON-DISCLOSURE AGREEMENT This MUTUAL NON-DISCLOSURE AGREEMENT is made and entered into as of this 8th day of August, 2018 (the “Effective Date”), between TESARO, Inc. |
|
| December 14, 2018 |
EX-99.(A)(1)(B) 3 d651999dex99a1b.htm EX-(A)(1)(B) Exhibit (a)(1)(b) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of TESARO, INC. at $75.00 Per Share Pursuant to the Offer to Purchase dated December 14, 2018 by ADRIATIC ACQUISITION CORPORATION, GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE PLC THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE PAST 11:59 P.M., EASTERN TIME, ON JANUA |
|
| December 14, 2018 |
EX-(a)(1)(d) Exhibit (a)(1)(d) Offer to Purchase All Outstanding Shares of Common Stock of TESARO, INC. |
|
| December 14, 2018 |
FIRST AMENDMENT TO THE MUTUAL NON-DISCLOSURE AGREEMENT EX-(d)(4) Exhibit (d)(4) FIRST AMENDMENT TO THE MUTUAL NON-DISCLOSURE AGREEMENT This First Amendment to the Mutual Non-Disclosure Agreement (“the Agreement”) dated the 8th day of August 2018 (this “First Amendment”) is made and entered into as of the 8th day of November 2018 (“Effective Date”), by and between TESARO, Inc. |
|
| December 14, 2018 |
3-WAY NON-DISCLOSURE AGREEMENT EX-(d)(5) Exhibit (d)(5) EXECUTION VERSION CONFIDENTIAL 3-WAY NON-DISCLOSURE AGREEMENT This 3-WAY NON-DISCLOSURE AGREEMENT is made and entered into as of this 15th day of November, 2018 (the “Effective Date”), among TESARO, Inc. |
|
| December 14, 2018 |
EX-(a)(1)(a) Table of Contents Exhibit (a)(1)(a) Offer To Purchase All Outstanding Shares of Common Stock of TESARO, Inc. |
|
| December 14, 2018 |
EX-(a)(1)(c) Exhibit (a)(1)(c) Offer to Purchase All Outstanding Shares of Common Stock of TESARO, INC. |
|
| December 14, 2018 |
GlaxoSmithKline Commences Tender Offer for TESARO, Inc. EX-99.(A)(5)(I) 8 d651999dex99a5i.htm EX-(A)(5)(I) Exhibit (a)(5)(i) GlaxoSmithKline Commences Tender Offer for TESARO, Inc. LONDON, UK—December 14, 2018—GlaxoSmithKline plc (LSE/NYSE: GSK) (“GSK”) today announced that it is commencing a cash tender offer for all of the issued and outstanding shares of common stock of TESARO, Inc. (NASDAQ: TRSO) (“TESARO”) for a price of $75.00 per share. The tend |
|
| December 14, 2018 |
EX-99.(A)(1)(F) 7 d651999dex99a1f.htm EX-(A)(1)(F) Exhibit (a)(1)(f) POWER OF ATTORNEY This Power of Attorney is granted on 22 November 2018 by GlaxoSmithKline plc (the “Company”), a company registered in England and Wales under number 3888792 and whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. 1. The Company hereby irrevocably authorises each of S |
|
| December 14, 2018 |
GSK / GlaxoSmithKline plc SC TO-T SC TO-T 1 d651999dsctot.htm SC TO-T SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TESARO, INC. (Name of Subject Company (Issuer)) ADRIATIC ACQUISITION CORPORATION, GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE PLC (Names of Filing Persons (Offerors)) Common Stock, par value $0.0001 pe |
|
| December 6, 2018 |
TSRO / TESARO, Inc. / NEW ENTERPRISE ASSOCIATES 13 LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* TESARO, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 881569107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Address and T |
|
| December 4, 2018 |
GSK / GlaxoSmithKline plc SC TO-C SC TO-C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TESARO, INC. (Name of Subject Company) ADRIATIC ACQUISITION CORPORATION, GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE PLC (Name of Filing Persons (Offerors)) Common Stock, par value $0.0001 per share (Title of Class of Securities) |
|
| December 4, 2018 |
Exhibit (A)(5)(G) Exhibit (A)(5)(G) Intent to acquire TESARO Q&A 1. Why does GSK want to acquire TESARO? There are a number of reasons GSK believes this would be an important, strategic acquisition. • Zejula is a high-quality PARP inhibitor with significant potential. It is proven commercially and is the first PARP inhibitor with a label for all recurrent ovarian cancer, including non-BRCA mutant |
|
| December 4, 2018 |
EX-99.(A)(5)(H) 4 d665281dex99a5h.htm EXHIBIT (A)(5)(H) The following was posted by GlaxoSmithKline on Facebook at https://www.facebook.com/pg/GSKItalia/posts/ on December 4, 2018. EXHIBIT (A)(5)(H) Additional Information This announcement is neither an offer to purchase nor a solicitation of an offer to sell securities. The tender offer for the issued and outstanding shares of common stock of the |
|
| December 4, 2018 |
Exhibit (A)(5)(F) Exhibit (A)(5)(F) GlaxoSmithKline Analyst Call Accelerating our priorities and building capabilities in Oncology GSK to acquire TESARO Monday, 3 December 2018 Cautionary Statement This communication is neither an offer to purchase nor a solicitation of an offer to sell securities. |
|
| December 4, 2018 |
Exhibit 99.1 TESARO, Inc. GIVES NOTICE OF ANTICIPATED MAKE-WHOLE ADJUSTMENT EVENT TO HOLDERS OF ITS CONVERTIBLE SENIOR NOTES Waltham, MA — DECEMBER 4, 2018 — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that, pursuant to the terms of the indenture (the “Indenture”) governing the terms of its 3.00% Convertible Senior notes due 2021 (the “Notes”), it ant |
|
| December 4, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of (Commission (I.R.S. Employer incorpo |
|
| December 4, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TESARO, Inc. (Name of Subject Company) TESARO, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (CUSIP Number of Common Stock) Leon |
|
| December 4, 2018 |
EX-99.1 2 a18-410163ex99d1.htm EX-99.1 Exhibit 99.1 Intent to acquire Tesaro Q&A 1. Why does GSK want to acquire Tesaro? There are a number of reasons GSK believes this would be an important, strategic acquisition. · Zejula is a high-quality PARP inhibitor with significant potential. It is proven commercially and is the first PARP inhibitor with a label for all recurrent ovarian cancer, including |
|
| December 4, 2018 |
EX-99.(A)(5)(A) 2 d641731dex99a5a.htm EXHIBIT (A)(5)(A) EXHIBIT (A)(5)(A) PRESS RELEASE Issued: 3 December 2018, London UK – LSE Announcement GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will ac |
|
| December 4, 2018 |
Exhibit (A)(5)(E) The following was posted by GlaxoSmithKline on Twitter at https://twitter. |
|
| December 4, 2018 |
Exhibit (A)(5)(D) EXHIBIT(A)(5)(D) Accelerating our priorities and building our capabilities in Oncology GSK to acquire TESARO 3 December 2018 EXHIBIT(A)(5)(D) Accelerating our priorities and building our capabilities in Oncology GSK to acquire TESARO 3 December 2018 Cautionary statements This presentation may contain forward-looking statements. |
|
| December 4, 2018 |
Exhibit (A)(5)(B) EXHIBIT (A)(5)(B) Subject line: Reaching even more patients together To everyone in the team at TESARO, This is a big day for all of us and I want to let you know we are absolutely thrilled that our companies have reached an agreement, which would join us together. |
|
| December 4, 2018 |
Newsflash to all Pharma from Hal Barron & Luke Miles Exhibit (A)(5)(C) EXHIBIT (A)(5)(C) Newsflash to all Pharma from Hal Barron & Luke Miles December 3 2018 Subject line: Delivering transformational medicines for patients Dear Colleagues, By now you will have seen the exciting announcement that GSK has reached an agreement to acquire TESARO, an oncology-focused biopharmaceutical company based in Waltham, near Boston. |
|
| December 4, 2018 |
GSK / GlaxoSmithKline plc SC TO-C SC TO-C 1 d641731dsctoc.htm SC TO-C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TESARO, INC. (Name of Subject Company) ADRIATIC ACQUISITION CORPORATION, GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE PLC (Name of Filing Persons (Offerors)) Common Stock, par value $0.0001 per share (T |
|
| December 3, 2018 |
Internal message to TESARO associates from Emma Exhibit 99.5 Internal message to TESARO associates from Emma Subject line: Reaching even more patients together To everyone in the team at TESARO, This is a big day for all of us and I want to let you know we are absolutely thrilled that our companies have reached an agreement, which would join us together. As part of the process to explore this opportunity, we’ve learned a lot about your company. |
|
| December 3, 2018 |
EX-99.1 2 a18-410162ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE Issued: 3 December 2018, London UK — LSE Announcement GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncol |
|
| December 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 TESARO, Inc. (Name of Subject Company) TESARO, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (CUSIP Number of Common Stock) Leon |
|
| December 3, 2018 |
Exhibit 99.4 RESPONSE TO INVESTOR INQUIRY Dear [x], Thank you for contacting TESARO. On December 3, 2018, GSK plc and TESARO, Inc., announced that the companies have entered into a definitive agreement under which GSK will acquire TESARO for approximately $5.1 billion, or $75 per share in cash. The transaction is expected to complete by the first quarter of 2019. Until then, TESARO will continue t |
|
| December 3, 2018 |
TESARO All Company Announcement Exhibit 99.2 TESARO Acquisition by GSK For distribution at 7:01am ET, Monday, December 3, 2018 Subject line: A new beginning TESARO All Company Announcement December 3, 2018 Dear TESARO Associates, This is a tremendous day for all of us at TESARO, Inc. This morning, we announced, together with GSK, that the companies have entered into a definitive agreement under which GSK will acquire TESARO for |
|
| December 3, 2018 |
TESARO Key Internal Messages (Town Halls) Exhibit 99.3 TESARO Key Internal Messages (Town Halls) · [This morning/earlier today/yesterday], we announced, together with GSK, that the companies have entered into a definitive agreement under which GSK will acquire TESARO for approximately $5.1 billion (£4.0 billion), or $75 per share. · This transaction and partnership marks a new beginning in the way we live out our mission, but it will not |
|
| December 3, 2018 |
EX-2.1 2 a18-410161ex2d1.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among GLAXOSMITHKLINE PLC, ADRIATIC ACQUISITION CORPORATION and TESARO, INC. Dated as of December 3, 2018 TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 Section 1.1. The Offer 2 Section 1.2. Company Actions; Schedule 14D-9 4 Section 1.3. Stockholder Lists 5 ARTICLE II THE MERGER 6 Section 2.1. The Merger 6 |
|
| December 3, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of (Commission (I.R.S. Employer incor |
|
| December 3, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 a18-4101618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of (Commissi |
|
| December 3, 2018 |
EX-99.1 3 a18-410161ex99d1.htm EX-99.1 Exhibit 99.1 Confidential FINAL FORM TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT, dated as of December [ ], 2018 (this “Agreement”), among GlaxoSmithKline plc, a public limited company incorporated in England and Wales (“Parent”), Adriatic Acquisition Corporation, a Delaware corporation and wholly-owned Subsidiary of Parent (“Purchaser”), and [S |
|
| December 3, 2018 |
EX-99.2 4 a18-410161ex99d2.htm EX-99.2 Exhibit 99.2 PRESS RELEASE Issued: 3 December 2018, London UK — LSE Announcement GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncol |
|
| December 3, 2018 |
EX-2.1 2 a18-410161ex2d1.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among GLAXOSMITHKLINE PLC, ADRIATIC ACQUISITION CORPORATION and TESARO, INC. Dated as of December 3, 2018 TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 Section 1.1. The Offer 2 Section 1.2. Company Actions; Schedule 14D-9 4 Section 1.3. Stockholder Lists 5 ARTICLE II THE MERGER 6 Section 2.1. The Merger 6 |
|
| November 2, 2018 |
Exhibit 10.1 AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT This Amendment No. 1 (this “Amendment”) to the Exclusive License Agreement, dated July 27, 2017 (the “Agreement”), between TESARO, Inc. (“TESARO”) and Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Ltd. (“Licensee”), is entered into as of July 16, 2018 (“Amendment Effective Date”). TESARO and |
|
| November 2, 2018 |
TSRO / TESARO, Inc. 10-Q (Quarterly Report) 10-Q 1 tsro-20180930x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition p |
|
| November 1, 2018 |
TESARO ANNOUNCES THIRD-QUARTER 2018 OPERATING RESULTS Exhibit 99.1 TESARO ANNOUNCES THIRD-QUARTER 2018 OPERATING RESULTS · ZEJULA® Q3 net sales totaled $63 million compared to $39 million for Q3 2017 · Top-line results for PRIMA trial of ZEJULA monotherapy for first-line ovarian cancer patients regardless of BRCA mutation status anticipated in late 2019 · Data presented at ESMO for TSR-042 indicate robust activity in patients with MSI-high endometria |
|
| November 1, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a18-3942118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Comm |
|
| September 5, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (State or other jurisdiction of (Commission (IRS Employer incorpora |
|
| September 5, 2018 |
Exhibit 99.1 FOR RELEASE ON SEPTEMBER 04, 2018 AT 4:15 PM ET TESARO ANNOUNCES EXPANSION TO SECOND STAGE OF JASPER TRIAL OF ZEJULA® IN COMBINATION WITH TSR-042 IN NON-SMALL CELL LUNG CANCER · All evaluable patients experienced tumor shrinkage · Protocol defined response criteria achieved and trial expansion ongoing WALTHAM, MA, September 4, 2018 — TESARO, Inc. (NASDAQ: TSRO), an oncology-focused bi |
|
| August 13, 2018 |
TSRO / TESARO, Inc. / Camber Capital Management LLC - PRIMARY DOCUMENT Passive Investment SC 13G 1 cambertsro201813g.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Tesaro, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (CUSIP Number) August 03, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| August 13, 2018 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated August 13, 2018 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| August 13, 2018 |
TSRO / TESARO, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G 1 d608133dsc13g.htm SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TESARO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 881569107 (CUSIP Number) August 8, 2018 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| August 3, 2018 |
Form of Restricted Stock Unit Agreement under 2015 Non-Employee Director Stock Incentive Plan. EX-10.2 2 tsro-20180630ex1022cb72e.htm EX-10.2 Exhibit 10.2 Award No.: TESARO, INC. 2015 Non-EMPLOYEE DIRECTOR STOCK INCENTIVE PLAN RESTRICTED Stock Unit Agreement COVER SHEET TESARO, Inc., a Delaware corporation (the “Company”), hereby grants restricted stock units (the “RSUs”) relating to shares of its common stock, par value $0.0001 per share (the “Stock”), to the individual named below, subjec |
|
| August 3, 2018 |
TSRO / TESARO, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| August 2, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of incorporation) (Commission File Number |
|
| August 2, 2018 |
TESARO ANNOUNCES SECOND-QUARTER 2018 OPERATING RESULTS Exhibit 99.1 TESARO ANNOUNCES SECOND-QUARTER 2018 OPERATING RESULTS · ZEJULA® Q2 net sales totaled $54 million compared to $26 million for Q2 2017 · QUADRA sNDA submission planned for Q4 2018 · PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of biomarker status enrollment completed · Divestiture completed for VARUBI in U.S. and Canada for $40 million plus potential m |
|
| July 18, 2018 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 a18-1739818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of (Commission |
|
| July 18, 2018 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On July 12, 2018, TESARO, Inc. (the “Company”) completed the sale to TerSera Therapeutics LLC (“TerSera”) of the Company’s rights to rolapitant (the “Sale”) in the United States and Canada (the “Territory”). The Sale was pursuant to the Asset Purchase Agreement (the “APA”) between the Company and TerSera previously annou |
|
| June 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 |
|
| June 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of incorporation) (Commission File Number) |
|
| June 5, 2018 |
EX-24.1 4 a18-145392ex24d1.htm EX-24.1 Exhibit 24.1 TESARO, INC. POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS that the undersigned Officers and Directors of TESARO, Inc., a Delaware corporation (the “Corporation”), hereby constitute and appoint Leon O. Moulder, Jr., Timothy R. Pearson and Joseph L. Farmer, and each of them, the true and lawful agents and attorneys-in-fact of the undersigned wi |
|
| June 5, 2018 |
As filed with the Securities and Exchange Commission on June 5, 2018 Registration No. |
|
| June 5, 2018 |
As filed with the Securities and Exchange Commission on June 5, 2018 Registration No. |
|
| June 5, 2018 |
Exhibit 24.1 TESARO, INC. POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS that the undersigned Officers and Directors of TESARO, Inc., a Delaware corporation (the “Corporation”), hereby constitute and appoint Leon O. Moulder, Jr., Timothy R. Pearson and Joseph L. Farmer, and each of them, the true and lawful agents and attorneys-in-fact of the undersigned with full power and authority in said age |
|
| May 11, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 |
|
| May 11, 2018 |
Exhibit 10.1 AMENDMENT TO THE TESARO, INC. 2012 EMPLOYEE STOCK PURCHASE PLAN The TESARO, Inc. 2012 Employee Stock Purchase Plan (the “ESPP”) is hereby amended as set forth below, effective as of the date of adoption (the “Adoption Date”) of this Amendment by the Board of Directors of TESARO, Inc. (the “Company”), subject to the approval of this Amendment by the stockholders of the Company, as prov |
|
| May 3, 2018 |
TESARO ANNOUNCES FIRST-QUARTER 2018 OPERATING RESULTS Exhibit 99.1 TESARO ANNOUNCES FIRST-QUARTER 2018 OPERATING RESULTS · ZEJULA Q1 net sales totaled $49 million · Enrollment completed in Phase 3 PRIMA first-line ovarian cancer monotherapy trial · TOPACIO platinum-resistant ovarian cancer and triple-negative breast cancer data accepted for oral presentations at ASCO · Initial data from two TSR-042 (anti-PD-1) GARNET expansion cohorts presented at AA |
|
| May 3, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 ( |
|
| May 3, 2018 |
TSRO / TESARO, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0 |
|
| May 3, 2018 |
EX-10.1 2 tsro-20180331ex1017a228d.htm EX-10.1 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Exhibit 10.1 SEVENTH AMENDMENT TO LEASE SEVENTH AMENDMENT TO LEASE (this “Seve |
|
| April 6, 2018 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 20, 2018 |
8-K 1 a18-852918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35587 (Commiss |
|
| March 14, 2018 |
TSRO / TESARO, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (State or other jurisdiction of (Commission (I.R.S. Employer incorpora |
|
| March 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* TESARO, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 881569107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Address and T |
|
| February 28, 2018 |
Exhibit 10.28 Amendment to Collaboration, Development and License Agreement THIS AMENDMENT TO COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT (the “Amendment”) is made and entered into as of February 26, 2018 by and among TESARO, Inc., a Delaware corporation (“TESARO Inc.”), TESARO Development Ltd., a Bermuda corporation (“TSRO Ltd.” and together with TESARO Inc., “TESARO”), and Zai Lab (Shanghai |
|
| February 28, 2018 |
Exhibit 21.1 Subsidiaries of the Company Legal Name Jurisdiction of Organization TESARO Securities Corporation* Massachusetts TESARO UK Limited* United Kingdom TESARO Development, Ltd.* Bermuda TESARO Bio GmbH* Switzerland TESARO Bio Germany GmbH* Germany TESARO Bio Italy S.r.l.* Italy TESARO Bio France SAS* France TESARO Bio Spain, S.L.* Spain TESARO Bio Netherlands B.V.* Netherlands TESARO Bio S |
|
| February 28, 2018 |
[***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. |
|
| February 28, 2018 |
[***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. |
|
| February 28, 2018 |
TSRO / TESARO, Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35587 |
|
| February 28, 2018 |
EX-10.38 4 tsro-20171231ex10389b632.htm EX-10.38 Exhibit 10.38 FIRST AMENDMENT TO LOAN AGREEMENT This First Amendment to the Loan Agreement (defined below) (this “Amendment”), dated as of February 7, 2018 (the “Effective Date”), is entered into by and among TESARO, INC., a Delaware corporation (as “Borrower”), TESARO SECURITIES CORPORATION, a Massachusetts corporation (as an additional Credit Part |
|
| February 28, 2018 |
Exhibit 10.37 LOAN AGREEMENT Dated as of November 21, 2017 between TESARO, INC. (as Borrower), TESARO SECURITIES CORPORATION (as an additional Credit Party), BIOPHARMA CREDIT PLC (as Collateral Agent and a Lender) and BIOPHARMA CREDIT INVESTMENTS IV SUB LP (as a Lender) LOAN AGREEMENT THIS LOAN AGREEMENT (this “Agreement”), dated as of November 21, 2017 (the “Effective Date”) by and among TESARO, |
|
| February 28, 2018 |
Amendment #2 to the TESARO, Inc. 2012 Omnibus Incentive Plan. Exhibit 10.4 AMENDMENT #2 TO THE TESARO, INC. 2012 OMNIBUS INCENTIVE PLAN The TESARO, Inc. 2012 Omnibus Incentive Plan (the “Plan”) is hereby amended as set forth below, effective as of the date of adoption (the “Adoption Date”) of this Amendment by the Board of Directors of TESARO, Inc. (the “Company”): 1.The seventh sentence of Section 18.3 of the Plan is deleted in its entirety and replaced wit |
|
| February 28, 2018 |
Computation of Ratio of Earnings to Fixed Charges. Exhibit 12.1 TESARO, Inc. CALCULATION OF EARNINGS TO FIXED CHARGES (UNAUDITED) Years Ended December 31, 2013 2014 2015 (a) 2016 (a) 2017 Earnings: (dollars in thousands) Income (Loss) from Operations before Income Taxes $ (92,362) $ (171,012) $ (247,749) $ (372,749) $ (494,802) Add: Fixed Charges 129 4,081 15,832 17,158 20,833 Total Earnings Available for Fixed Charges $ (92,233) $ (166,931) $ (23 |
|
| February 27, 2018 |
TESARO ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 OPERATING RESULTS Exhibit 99.1 TESARO ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 OPERATING RESULTS ? ZEJULA is the #1 PARP inhibitor for women with ovarian cancer in the U.S. ? 2017 ZEJULA? net sales totaled $109 million during first nine months of commercial launch ? Focused clinical development program for niraparib in ovarian cancer is advancing in first-line and platinum-resistant settings ? Multiple immuno-on |
|
| February 27, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a18-718618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Comm |
|
| February 12, 2018 |
TSRO / TESARO, Inc. / VANGUARD GROUP INC Passive Investment tesaroinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: TESARO Inc Title of Class of Securities: Common Stock CUSIP Number: 881569107 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate box to designate th |
|
| February 8, 2018 |
TSRO / TESARO, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* TESARO, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 881569107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 5, 2018 |
TSRO / TESARO, Inc. / FRANKLIN RESOURCES INC Passive Investment tesa17a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 881569107 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TESARO, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (CUSIP Number) December 31, 2017 (Date of Event |
|
| February 2, 2018 |
TSRO / TESARO, Inc. / VANGUARD SPECIALIZED FUNDS Passive Investment tesaroinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.:0 )* Name of issuer: TESARO Inc Title of Class of Securities: Common Stock CUSIP Number: 881569107 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate box to designate the |
|
| February 2, 2018 |
TESARO TO ANNOUNCE FOURTH-QUARTER 2017 FINANCIAL RESULTS ON FEBRUARY 27, 2018 Exhibit 99.1 FOR RELEASE ON FEBRUARY 2, 2018 TESARO TO ANNOUNCE FOURTH-QUARTER 2017 FINANCIAL RESULTS ON FEBRUARY 27, 2018 WALTHAM, MA ? February 2, 2018 ? TESARO, Inc. (NASDAQ: TSRO) will announce fourth-quarter 2017 financial results on Tuesday, February 27, 2018, after the close of the U.S. financial markets. During the conference call and live audio webcast at 4:15 p.m. ET on February 27, 2018 |
|
| February 2, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a18-530718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35587 (Commi |
|
| January 16, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a18-320018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35587 (Commi |
|
| January 16, 2018 |
Exhibit 99.1 TESARO Announces Updates to the U.S. Prescribing Information for VARUBI? (rolapitant) Injectable Emulsion WALTHAM, Mass., Jan. 12, 2018 ? TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has updated the VARUBI? (rolapitant) injectable emulsion package insert in collaboration with the U.S. Food and Drug Administration (FDA). VARUBI inje |
|
| January 8, 2018 |
January 2018 Investor Meetings Exhibit 99.1 January 2018 Investor Meetings Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as " |
|
| January 8, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a18-238418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2018 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of incorporati |
|
| December 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249 |
|
| November 21, 2017 |
TSRO / TESARO, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-224 |
|
| November 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249 |
|
| November 7, 2017 |
TSRO / TESARO, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249 |
|
| November 7, 2017 |
TESARO ANNOUNCES THIRD-QUARTER 2017 OPERATING RESULTS Exhibit 99.1 TESARO ANNOUNCES THIRD-QUARTER 2017 OPERATING RESULTS ? ZEJULA? was the most prescribed PARP inhibitor in U.S. with Q3 net sales of $39.4 million ? Positive CHMP opinion issued for ZEJULA in E.U.; commercial launch anticipated to begin by year-end ? Expansion of niraparib development program underway for multiple tumor types ? VARUBI? IV approved by U.S. FDA; commercial launch planned |
|
| November 7, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| November 7, 2017 |
[***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. |
|
| October 27, 2017 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of incorporation) (Commission File Numb |
|
| October 27, 2017 |
Exhibit 99.1 TESARO ANNOUNCES U.S. FDA APPROVAL OF VARUBI? IV FOR DELAYED NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY ? VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administration ? Availability of new formulation offers healthcare providers the flexibility to choose oral or IV administration ? VARUBI provides enhanced control of delayed CINV as |
|
| September 18, 2017 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-22 |
|
| September 18, 2017 |
TESARO RECEIVES POSITIVE CHMP OPINION FOR ZEJULA® Exhibit 99.1 TESARO RECEIVES POSITIVE CHMP OPINION FOR ZEJULA? ZUG, SWITZERLAND, September 15, 2017 ? TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency?s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the Company?s marketing authorization application (MAA) for ZEJULA? (nirapa |
|
| September 11, 2017 |
TSRO / TESARO, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - TSRO AS OF 08/31/2017 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) TESARO INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 881569107 (CUSIP Number) August 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [ |
|
| August 10, 2017 |
TSRO / TESARO, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* TESARO, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 881569107 (CUSIP Number) July 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| August 8, 2017 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-224968 |
|
| August 8, 2017 |
TESARO ANNOUNCES SECOND-QUARTER 2017 OPERATING RESULTS Exhibit 99.1 TESARO ANNOUNCES SECOND-QUARTER 2017 OPERATING RESULTS ? ZEJULA is the most prescribed PARP inhibitor in U.S.; Q2 net sales totaled $26 million in first quarter of availability ? Recently opened European niraparib EAP has enrolled 200 patients ? VARUBY oral launch now underway in Europe ? Dose-escalation of TSR-022 (anti-TIM-3) completed and combination trial with TSR-042 (anti-PD-1) |
|
| August 8, 2017 |
[***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. |
|
| August 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| July 27, 2017 |
8-K 1 a17-1846518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commiss |
|
| July 27, 2017 |
Exhibit 99.1 TESARO AND TAKEDA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE NOVEL CANCER THERAPY NIRAPARIB IN JAPAN ? Takeda?s Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia ? TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial |
|
| June 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 |
|
| June 5, 2017 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 |
|
| June 5, 2017 |
TESARO PROVIDES BUSINESS AND PIPELINE UPDATE AT ASCO INVESTOR BRIEFING EX-99.1 2 a17-147381ex99d1.htm EX-99.1 Exhibit 99.1 For Release on June 3, 2017 at 5:30 PM CT TESARO PROVIDES BUSINESS AND PIPELINE UPDATE AT ASCO INVESTOR BRIEFING · Initial TOPACIO data for niraparib plus KEYTRUDA® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancer · Phase 1 results for TSR-042 show anti-PD-1 activity · Three posters presented durin |
|
| May 12, 2017 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of incorporation) (Commission File Number) |
|
| May 10, 2017 |
Exhibit 99.1 Q1 2017 EARNINGS SCRIPT TESARO, INC. SLIDE 1 ? TITLE SLIDE OPERATOR: Good afternoon, and welcome to the TESARO first-quarter 2017 conference call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and web cast. I?ll now turn the call over to Jennifer Davis, Vice President of Investor Relations and Corporate Affairs at TESARO. Please g |
|
| May 10, 2017 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 ( |
|
| May 9, 2017 |
TESARO 10-Q (Quarterly Report) tsroCurrentFolio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35587 TESARO, INC. |
|
| May 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 ( |
|
| May 9, 2017 |
TESARO ANNOUNCES FIRST-QUARTER 2017 OPERATING RESULTS Exhibit 99.1 TESARO ANNOUNCES FIRST-QUARTER 2017 OPERATING RESULTS ? ZEJULA? approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underway ? ZEJULA added to the NCCN Clinical Practice Guidelines in Oncology ? Expanded development program for niraparib in ovarian, lung and breast cancers to begin 2H 2017 |
|
| May 9, 2017 |
EX-10.2 3 tsro-20170331ex10219c6c4.htm EX-10.2 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Exhibit 10.2 MASTER SUPPLY AGREEMENT This MASTER SUPPLY AGREEMENT (“Agreement” |
|
| May 9, 2017 |
EX-10.4 5 tsro-20170331ex104f58927.htm EX-10.4 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Exhibit 10.4 DRUG PRODUCT SUPPLY AGREEMENT Between TESARO Bio GmbH And Charles |
|
| May 9, 2017 |
EX-10.3 4 tsro-20170331ex103189a24.htm EX-10.3 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Exhibit 10.3 COMMERCIAL SUPPLY AGREEMENT This COMMERCIAL SUPPLY AGREEMENT is e |
|
| May 9, 2017 |
EX-10.1 2 tsro-20170331ex1018ad8e7.htm EX-10.1 Exhibit 10.1 FIFTH AMENDMENT TO LEASE FIFTH AMENDMENT TO LEASE (this “Fifth Amendment”) dated as of this 9th day of February, 2017 by and between BP BAY COLONY LLC, a Delaware limited liability company (“Landlord”), and TESARO, INC., a Delaware corporation (“Tenant”). RECITALS By Lease dated October 15, 2012 (the “Lease”), Landlord did lease to Tenant |
|
| April 7, 2017 |
Use these links to rapidly review the document TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 31, 2017 |
Exhibit 99.2 TESARO ANNOUNCES EXPANDED DEVELOPMENT PROGRAM FOR NIRAPARIB FOCUSED ON THE TREATMENT OF FRONT-LINE METASTATIC OVARIAN AND LUNG CANCERS AND METASTATIC BREAST CANCER · Expanded niraparib ovarian cancer program intended to potentially transform the treatment of front-line ovarian cancer · New breast cancer clinical program for niraparib to address greatest area of unmet need and broader |
|
| March 31, 2017 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-224968 |
|
| March 31, 2017 |
TESARO ANNOUNCES U.S. FDA APPROVAL OF ZEJULA™ (NIRAPARIB) FOR WOMEN WITH RECURRENT OVARIAN CANCER Exhibit 99.1 TESARO ANNOUNCES U.S. FDA APPROVAL OF ZEJULA? (NIRAPARIB) FOR WOMEN WITH RECURRENT OVARIAN CANCER ? ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancer ? Use of ZEJULA does not require patient selection with a biomarker test ? U.S. commercial launch planned for late April ? Investor conference call and webcast |
|
| March 22, 2017 |
TESARO 10-Q/A (Quarterly Report) 10-Q/A 1 tsro10qaq316cover.htm 10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
| March 22, 2017 |
COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT tsroEx101 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. |
|
| March 1, 2017 |
TESARO, INC. SECTION 16 POWER OF ATTORNEY TESARO, INC. SECTION 16 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Timothy R. Pearson, Joseph L. Farmer and Edward C. English, each for so long as he is an officer of TESARO, Inc. (the "Company"), the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a |
|
| February 28, 2017 |
10-K 1 tsro-20161231x10k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2016 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t |
|
| February 28, 2017 |
TESARO, Inc. CALCULATION OF EARNINGS TO FIXED CHARGES Exhibit 12.1 TESARO, Inc. CALCULATION OF EARNINGS TO FIXED CHARGES (UNAUDITED) Years Ended December 31, 2012 2013 2014 2015 2016 Earnings: (dollars in thousands) Income (Loss) from Operations before Income Taxes $ (61,763) $ (92,362) $ (171,012) $ (251,408) $ (385,997) Add: Fixed Charges 33 129 4,081 15,832 17,158 Total Earnings Available for Fixed Charges $ (61,730) $ (92,233) $ (166,931) $ (235, |
|
| February 28, 2017 |
Exhibit 21.1 Subsidiaries of the Company Legal Name Jurisdiction of Organization TESARO Securities Corporation* Massachusetts TESARO UK Limited* United Kingdom TESARO Development, Ltd.* Bermuda TESARO Bio GmbH* Switzerland TESARO Bio Germany GmbH* Germany TESARO Bio Italy S.r.l.* Italy TESARO Bio France SAS* France TESARO Bio Spain, S.L.* Spain TESARO Bio Netherlands B.V.* Netherlands *The above n |
|
| February 28, 2017 |
EX-10.38 9 tsro-20161231ex103821c31.htm EX-10.38 Exhibit 10.38 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. SECOND AMENDMENT TO LEASE SECOND AMENDMENT TO LEASE (this “Sec |
|
| February 28, 2017 |
Exhibit 10.16 TESARO, INC. 1000 Winter Street, Suite 3300 Waltham, Massachusetts 02451 February 23, 2017 Mary Lynne Hedley, Ph.D. President and Chief Operating Officer TESARO, Inc. 1000 Winter Street, Suite 3300 Waltham, Massachusetts 02451 Dear Mary Lynne: On behalf of TESARO, Inc. (the “Company”), I am very pleased to offer you an amended and restated employment letter in connection with your on |
|
| February 28, 2017 |
EX-10.25 5 tsro-20161231ex1025b476c.htm EX-10.25 Exhibit 10.25 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT This Am |
|
| February 28, 2017 |
Exhibit 10.8 TESARO, Inc. 2015 NON-EMPLOYEE DIRECTOR STOCK INCENTIVE PLAN TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 6 3.1 Committee 6 3.1.1 Powers and Authorities 6 3.1.2 Composition of the Committee 6 3.2 Board 6 3.3 Terms of Awards 7 3.3.1 Committee Authority 7 3.3.2 Forfeiture; Recoupment 7 3.4 No Repricing Without Stockholder Approval 8 3.5 Deferral Arr |
|
| February 28, 2017 |
TESARO ANNOUNCES FOURTH-QUARTER 2016 OPERATING RESULTS Exhibit 99.1 FOR RELEASE ON FEBRUARY 28, 2017 AT 4:05 PM ET TESARO ANNOUNCES FOURTH-QUARTER 2016 OPERATING RESULTS ? Niraparib NDA under review by FDA; pre-launch preparations for planned commercial launch well underway ? Expanded access program (EAP) for niraparib open in U.S.; European EAP expected to open 1H 2017 ? Positive opinion rendered for VARUBY? by the European Medicine Agency?s CHMP; Eu |
|
| February 28, 2017 |
EX-10.17 4 tsro-20161231ex101727882.htm EX-10.17 Exhibit 10.17 TESARO, Inc. │ 1000 Winter St, Suite 3300 │Waltham, MA 02451 [Date] PERSONAL AND CONFIDENTIAL [Name] [Address] Dear [Name]: On behalf of TESARO, Inc. (the “Company”), I am very pleased to offer you an amended and restated employment letter in connection with your ongoing employment in the position of [TITLE]. The terms of your position |
|
| February 28, 2017 |
Exhibit 10.15 TESARO, INC. 1000 Winter Street, Suite 3300 Waltham, Massachusetts 02451 February 23, 2017 Mr. Leon O. Moulder, Jr. Chief Executive Officer TESARO, Inc. 1000 Winter Street, Suite 3300 Waltham, Massachusetts 02451 Dear Lonnie: On behalf of TESARO, Inc. (the “Company”), I am very pleased to offer you an amended and restated employment letter in connection with your ongoing employment i |
|
| February 28, 2017 |
Exhibit 10.39 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THIRD AMENDMENT TO LEASE THIRD AMENDMENT TO LEASE (this “Third Amendment”) dated as of this 2nd day of August, |
|
| February 28, 2017 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-224 |
|
| February 28, 2017 |
EX-10.26 6 tsro-20161231ex1026faaa1.htm EX-10.26 Exhibit 10.26 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXECUTION COPY COLLABORATION, DEVELOPMENT AND LICENSE AGREEMEN |
|
| February 28, 2017 |
EX-10.37 8 tsro-20161231ex1037b9b07.htm EX-10.37 Exhibit 10.37 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. FIRST AMENDMENT TO LEASE FIRST AMENDMENT TO LEASE dated as of |
|
| February 28, 2017 |
Exhibit 10.36 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. BAY COLONY CORPORATE CENTER 1000 WINTER STREET WALTHAM, MASSACHUSETTS Lease Dated October 15, 2012 THIS INSTRUM |
|
| February 28, 2017 |
Exhibit 10.40 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. FOURTH AMENDMENT TO LEASE FOURTH AMENDMENT TO LEASE (this “Fourth Amendment”) dated as of this 6th day of Octob |
|
| February 14, 2017 |
EX-99.1 2 t19759224b.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behal |
|
| February 14, 2017 |
TSRO / TESARO, Inc. / Point72 Asset Management, L.P. - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TESARO, INC. (Name of Issuer) Common Stock Par Value $0.0001 Per Share (Title of Class of Securities) 881569107 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 10, 2017 |
TESARO 3G (Passive Acquisition of More Than 5% of Shares) tesaroinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: TESARO Inc Title of Class of Securities: Common Stock CUSIP Number: 881569107 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check the appropriate box to designate th |
|
| February 9, 2017 |
TSRO / TESARO, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* TESARO, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 881569107 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 7, 2017 |
TSRO / TESARO, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G 1 tesa16in.htm CUSIP NO. 881569107 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TESARO, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 881569107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this State |
|
| January 12, 2017 |
TESARO RECEIVES COMPLETE RESPONSE LETTER FOR ROLAPITANT IV FROM U.S. FDA Exhibit 99.1 FOR RELEASE ON JANUARY 11, 2017 TESARO RECEIVES COMPLETE RESPONSE LETTER FOR ROLAPITANT IV FROM U.S. FDA ? No concerns raised by FDA related to the rolapitant IV efficacy or safety profile and additional clinical studies are not required ? Investor conference call and webcast scheduled for tomorrow at 8:30AM ET WALTHAM, MA, January 11, 2017 ? TESARO, Inc. (NASDAQ: TSRO), an oncology-f |
|
| January 12, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of incorporation) (Commission File Numb |
|
| January 9, 2017 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2017 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 18, 2016 |
TESARO, Inc. 1,750,000 Shares Common Stock ($0.0001 par value) Underwriting Agreement Exhibit 1.1 TESARO, Inc. 1,750,000 Shares Common Stock ($0.0001 par value) Underwriting Agreement New York, New York November 15, 2016 Citigroup Global Markets Inc., Leerink Partners LLC, Credit Suisse Securities (USA) LLC, and Wells Fargo Securities, LLC As Representatives of the several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Leerink Partn |
|
| November 18, 2016 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of incorporation) (Commission File Num |
|
| November 17, 2016 |
Use these links to rapidly review the document TABLE OF CONTENTS ABOUT THIS PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| November 14, 2016 |
SUBJECT TO COMPLETION, DATED NOVEMBER 14, 2016 Use these links to rapidly review the document TABLE OF CONTENTS ABOUT THIS PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| November 4, 2016 |
TESARO 10-Q (Quarterly Report) 10-Q 1 tsro-20160930x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per |
|
| November 4, 2016 |
COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. |
|
| November 3, 2016 |
TESARO ANNOUNCES THIRD-QUARTER 2016 OPERATING RESULTS Exhibit 99.1 FOR RELEASE ON NOVEMBER 3, 2016 AT 4:05 PM ET TESARO ANNOUNCES THIRD-QUARTER 2016 OPERATING RESULTS ? Niraparib rolling NDA submission to FDA complete, MAA accepted for review by EMA ? Pre-launch planning ongoing to support four potential product launches in 2017 across U.S. and Europe ? Positive Phase 3 NOVA trial results presented during Presidential Symposium at ESMO 2016 and simul |
|
| November 3, 2016 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of (Commission (I.R.S. Employer incorpo |
|
| September 29, 2016 |
TESARO AND ZAI LAB ANNOUNCE COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT Exhibit 99.1 TESARO AND ZAI LAB ANNOUNCE COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT · Collaboration enables the clinical development of niraparib in China by Zai Lab · TESARO retains right to co-market in China and receives option to license up to two novel immuno-oncology programs outside China WALTHAM, MA, AND SHANGHAI, September 29, 2016 TESARO, Inc. (NASDAQ: TSRO), an oncology-focused |
|
| September 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-22 |
|
| August 5, 2016 |
TESARO 10-Q (Quarterly Report) 10-Q 1 tsro-20160630x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f |
|
| August 5, 2016 |
EX-10.3 5 tsro-20160630ex103eb9aec.htm EX-10.3 Exhibit 10.3 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Execution Copy AMENDMENT NO. 1 TO LICENSE AGREEMENT This AMENDMEN |
|
| August 5, 2016 |
Exhibit 10.1 [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN TESARO, INC. AND JANSSEN BIOTECH, INC. TABLE OF CONTENTS Page |
|
| August 5, 2016 |
EX-4.1 2 tsro-20160630ex41a212a80.htm EX-4.1 Exhibit 4.1 INVESTOR AGREEMENT INVESTOR AGREEMENT THIS INVESTOR AGREEMENT (this “Agreement”) is made as of April 5, 2016, by and between TESARO, Inc., a Delaware corporation (the “Company”), and Johnson & Johnson Innovation-JJDC, Inc., a New Jersey corporation (the “Investor”). WHEREAS, the Stock Purchase Agreement, dated as of the date hereof, by and b |
|
| August 5, 2016 |
EX-10.2 4 tsro-20160630ex102442380.htm EX-10.2 Exhibit 10.2 STOCK PURCHASE AGREEMENT Table of Contents Page Section 1. Purchase and Sale of Common Stock 1 1.1 Sale and Issuance of Common Stock 1 1.2 Closing; Delivery 1 1.3 Defined Terms Used in this Agreement 1 1.4 Construction 3 Section 2. Representations and Warranties of the Company 4 2.1 Organization and Power 4 2.2 Authorization 4 2.3 No Conf |
|
| August 4, 2016 |
TESARO ANNOUNCES SECOND-QUARTER 2016 OPERATING RESULTS Exhibit 99.1 FOR RELEASE ON AUGUST 4, 2016 AT 4:05 PM ET TESARO ANNOUNCES SECOND-QUARTER 2016 OPERATING RESULTS ? Positive Phase 3 data reported by TESARO and ENGOT from the NOVA trial of niraparib in a broad population of patients with platinum-sensitive, recurrent ovarian cancer ? Pre-launch planning underway to support four potential product launches in 2017 across U.S. and Europe ? Expansion o |
|
| August 4, 2016 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-224968 |
|
| July 7, 2016 |
TESARO, Inc. 4,650,000 Shares Common Stock ($0.0001 par value) Underwriting Agreement Exhibit 1.1 TESARO, Inc. 4,650,000 Shares Common Stock ($0.0001 par value) Underwriting Agreement New York, New York June 30, 2016 Citigroup Global Markets Inc., Leerink Partners LLC, Credit Suisse, and Wells Fargo Securities, LLC As Representatives of the several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Leerink Partners LLC One Federal Stree |
|
| July 7, 2016 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of incorporation) (Commission File Number) |
|
| July 5, 2016 |
424B5 1 a2229102z424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-212324 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be Registered(1)(2) Proposed Maximum Offering Price per Share Proposed Maximum Aggregate Offering Price(1)(2) Amount of Registration Fee Common Stock, par value $0.0001 per share 5,347,500 $81.00 |
|
| June 30, 2016 |
RATIO OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERENCE DIVIDENDS (unaudited) Exhibit 12.1 RATIO OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERENCE DIVIDENDS (unaudited) Years Ended December 31, Quarter Ended March 31, (dollars in thousands) 2011 2012 2013 2014 2015 2016 Earnings: Income (Loss) from Operations before Income Taxes $ (16,398 ) $ (61,763 ) $ (92,362 ) $ (171,012 ) $ (251,408 ) $ (90,767 ) Add: Fixed Charges 15 33 129 4,081 15,832 4,099 Total Earnings Availab |
|
| June 30, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of incorporation) (Commission File Number) |
|
| June 30, 2016 |
CALCULATION OF REGISTRATION FEE Table of Contents Filed pursuant to Rule424(b)(7) Registration No.333-212324 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities To Be Registered Amount To Be Registered(1) Proposed Maximum Offering Price Per Security(2) Proposed Maximum Aggregate Offering Price Amount of Registration Fee(3) Common Stock, par value $0.0001 per share 1,420,857 shares $39.30 $55,839,680.10 $5,623.06 (1 |
|
| June 30, 2016 |
Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE o Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 31-0841368 I.R.S. Employer Identif |
|
| June 30, 2016 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on June 30, 2016 Registration No. |
|
| June 30, 2016 |
SUBJECT TO COMPLETION, DATED JUNE 30, 2016 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-212324 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these secu |
|
| June 29, 2016 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 |
|
| June 29, 2016 |
EX-99.1 2 a16-142441ex99d1.htm EX-99.1 Exhibit 99.1 TESARO’S NIRAPARIB SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL FOR PATIENTS WITH OVARIAN CANCER IN BOTH COHORTS OF THE PHASE 3 NOVA TRIAL · The NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort · The NOVA trial successfully achieved its primary endpoint of PFS in the non-germline BRCA mutant coho |
|
| June 6, 2016 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 |
|
| June 6, 2016 |
TESARO PROVIDES PIPELINE UPDATE AT ASCO INVESTOR BRIEFING Exhibit 99.1 FOR RELEASE ON JUNE 4, 2016, AT 7:00 PM ET TESARO PROVIDES PIPELINE UPDATE AT ASCO INVESTOR BRIEFING ? Rolapitant IV NDA accepted for review by FDA; PDUFA date is January 11, 2017 ? Sufficient PFS events reached for data analysis of both cohorts of Phase 3 niraparib NOVA trial; data expected in Q2 2016 ? IND for TSR-022 (anti-TIM-3 antibody) cleared by FDA; Phase 1 study to begin in m |
|
| May 13, 2016 |
TESARO 8-K/A (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-224968 |
|
| May 12, 2016 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 |
|
| May 10, 2016 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| May 10, 2016 |
TSRO / TESARO, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TESARO, INC. (Name of Issuer) Par Value $0.0001 Per Share (Title of Class of Securities) 881569107 (CUSIP Number) May 9, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| May 6, 2016 |
TESARO 10-Q (Quarterly Report) tsroCurrentFolio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35587 TESARO, INC. |
|
| May 6, 2016 |
EX-4.2 3 tsro-20160331ex420b1e410.htm EX-4.2 Exhibit 4.2 INVESTOR AGREEMENT INVESTOR AGREEMENT THIS INVESTOR AGREEMENT (this “Agreement”) is made as of March 18, 2016, by and among TESARO, Inc., a Delaware corporation (the “Company”), The Northern Trust Company in its capacity as custodian (the “FF Investor”) for the Future Fund Investment Company No.4 Pty Ltd (ACN 134 338 926) of Level 43, 120 Co |
|
| May 6, 2016 |
EX-10.2 5 tsro-20160331ex1024bf8c6.htm EX-10.2 Exhibit 10.2 AMENDMENT NO. 2 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT This Amendment No. 2 to the Collaboration and Exclusive License Agreement (this “Amendment”) effective as of February 29, 2016 (the “Amendment Date”), is entered into is made by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10421 Pac |
|
| May 6, 2016 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT Table of Contents Page Section 1. Purchase and Sale of Common Stock 1 1.1 Sale and Issuance of Common Stock 1 1.2 Closing; Delivery 1 1.3 Defined Terms Used in this Agreement 1 1.4 Construction 6 Section 2. Representations and Warranties of the Company 6 2.1 Organization and Power 6 2.2 Authorization 6 2.3 No Conflicts; Consents and Approvals; No Violation 7 2 |
|
| May 6, 2016 |
EX-4.1 2 tsro-20160331ex41b8e0b99.htm EX-4.1 Exhibit 4.1 Amendment No. 2 To SECOND Amended and Restated INVESTORS’ RIGHTS Agreement The Second Amended and Restated Investors’ Rights Agreement (as amended, the “Agreement”), dated as of June 6, 2011, among TESARO, INC., a Delaware corporation (the “Company”), the investors listed on Schedule A thereto (the “Investors”), OPKO Health, Inc., a Delaware |
|
| May 5, 2016 |
TESARO ANNOUNCES FIRST-QUARTER 2016 OPERATING RESULTS Exhibit 99.1 FOR RELEASE ON MAY 5, 2016 AT 4:05 PM ET TESARO ANNOUNCES FIRST-QUARTER 2016 OPERATING RESULTS ? U.S. launch of VARUBI? underway; New Drug Application (NDA) for IV formulation of rolapitant submitted ? Niraparib Phase 3 NOVA results anticipated in Q2 2016 are positioned to be the first data from a randomized, prospective Phase 3 trial of a PARP inhibitor ? NDA and MAA submissions for |
|
| May 5, 2016 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 ( |
|
| April 11, 2016 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-2249687 |
|
| April 11, 2016 |
TESARO ANNOUNCES GLOBAL PROSTATE CANCER COLLABORATION AND LICENSING AGREEMENT WITH JANSSEN EX-99.1 2 a16-81841ex99d1.htm EX-99.1 Exhibit 99.1 April 6, 2016 TESARO ANNOUNCES GLOBAL PROSTATE CANCER COLLABORATION AND LICENSING AGREEMENT WITH JANSSEN · Janssen to develop and commercialize niraparib for patients with prostate cancer worldwide, except in Japan · TESARO to receive up to $450 million in upfront and milestone payments, plus royalties · Janssen to fund all development and commerc |
|
| April 8, 2016 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 4, 2016 |
TESARO 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-224968 |
|
| April 4, 2016 |
TESARO, INC. SECTION 16 POWER OF ATTORNEY Exhibit 24 TESARO, INC. SECTION 16 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Timothy R. Pearson, Joseph L. Farmer and Edward C. English, each for so long as he is an officer of TESARO, Inc. (the ?Company?), the undersigned?s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s ca |
|
| March 28, 2016 |
TSRO / TESARO, Inc. / NEW ENTERPRISE ASSOCIATES 13 LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* TESARO, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 881569 107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Address and |
|
| March 16, 2016 |
CORPORATE PRESENTATION March 2016 Exhibit 99.1 CORPORATE PRESENTATION March 2016 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such a |
|
| March 16, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware (state or other jurisdiction of incorporation) 001-35587 (Commission File Number) 27-224968 |
|
| March 14, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2016 TESARO, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35587 27-2249687 (state or other jurisdiction of incorporation) (Commission File Number |
|
| March 14, 2016 |
Exhibit 99.1 TESARO SUBMITS NEW DRUG APPLICATION FOR INTRAVENOUS ROLAPITANT TO THE U.S. FOOD AND DRUG ADMINISTRATION WALTHAM, MA, March 14, 2016 ? TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA) for an intravenous (IV) formulation of rolapitant to the U.S. Food and Drug Administration (FDA). Rolapitant |
|
| March 10, 2016 |
TESARO TSRO AS OF 02/29/2016 (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) TESARO INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 881569107 (CUSIP Number) February 29, 2016 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: |
|
| March 10, 2016 |
TSRO / TESARO, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* TESARO, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 881569107 (CUSIP Number) February 29, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 29, 2016 |
EX-21.1 7 tsro-20151231ex21184856e.htm EX-21.1 Exhibit 21.1 Subsidiaries of the Company Legal Name Jurisdiction of Organization TESARO Securities Corporation* Massachusetts TESARO UK Limited* United Kingdom TESARO Development, Ltd.* Bermuda TSRO Bio GmbH* Switzerland *The above named subsidiary does business only under its legal name. |
